Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
Yi MiaoYeqin ShaYi XiaShuchao QinRui JiangLuomengjia DaiHui ShenTonglu QiuWei WuJingyan QiuYilian YangChongyang DingYujie WuLei FanWei XuJian-Yong LiHuayuan ZhuPublished in: Blood cancer journal (2023)